LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
21/01/26	19.52 $	+0.70%	84,376
20/01/26	19.38 $	+5.96%	1,255,238
16/01/26	18.29 $	+0.83%	1,254,844
15/01/26	18.14 $	-2.42%	1,197,547
14/01/26	18.59 $	+11.99%	1,815,804

Delayed Quote Nasdaq, January 21, 2026 at 07:04 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.38USD

Average target price

53.71USD

Spread / Average Target

+177.16%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 19:18:14 21/01/2026 +04			5-day change	1st Jan Change
19.46 ^USD	+0.41%		+4.98%	+21.97%

01-14	Lenz Therapeutics launch of "Make It Vizzable" with Sarah Jessica Parker as a brand ambassador	RE
01-05	LENZ Therapeutics, Inc. and Lunatus Marketing & Consulting FZCO Announce Exclusive Commercialization Partnership for VIZZ?? in the Middle East	CI

Capitalization	606M 517M 479M 450M 838M 55.19B 899M 5.53B 2.18B 26.24B 2.27B 2.23B 95.77B	P/E ratio 2025 *	-7.37x	P/E ratio 2026 *	-7.39x
Enterprise value	606M 517M 479M 450M 838M 55.19B 899M 5.53B 2.18B 26.24B 2.27B 2.23B 95.77B	EV / Sales 2025 *	31.8x	EV / Sales 2026 *	11.6x
Free-Float	97.14%	Yield 2025 *	-	Yield 2026 *	-

01-14	Lenz Therapeutics launch of "Make It Vizzable" with Sarah Jessica Parker as a brand ambassador	RE
01-05	LENZ Therapeutics, Inc. and Lunatus Marketing & Consulting FZCO Announce Exclusive Commercialization Partnership for VIZZ?? in the Middle East	CI
01-05	Lenz Therapeutics Reports Vizz Distribution Deal in the Middle East	MT
01-05	Lenz Therapeutics and Lunatus announce partnership for Vizz(TM)	RE
12-04	LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10:30 AM
12-01	Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea	MT
12-01	Enz Therapeutics submits NDA for LNZ100 (Vizz) in South Korea to treat presbyopia	RE
12-01	Lenz Therapeutics Announces Mfds Submission of New Drug Application for Lnz100 (Vizz??) in South Korea for the Treatment of Presbyopia	CI
11-05	LENZ Therapeutics, Inc., Q3 2025 Earnings Call, Nov 05, 2025
11-05	LENZ Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	LENZ Therapeutics' Q3 Net Loss Widens	MT
11-05	Earnings Flash (LENZ) Lenz Therapeutics Posts Q3 Net Loss $0.59 a Share	MT
11-05	LENZ Therapeutics Q3 net loss widens on increased SG&A expenses	RE

18/03/25	TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target	MT
27/09/24	Raymond James Initiates LENZ Therapeutics at Outperform With $37 Price Target	MT
12/08/24	HC Wainwright Initiates LENZ Therapeutics at Buy With $38 Price Target	MT
15/04/24	Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	MT
15/04/24	William Blair Starts LENZ Therapeutics With Outperform Rating	MT

LENZ Therapeutics, Inc. Stock

Equities

LENZ

US52635N1037

Biotechnology & Medical Research

Valuation: LENZ Therapeutics, Inc.

Chart: LENZ Therapeutics, Inc.

Latest news: LENZ Therapeutics, Inc.

Last Transcript: LENZ Therapeutics, Inc.

Analysts' recommendations: LENZ Therapeutics, Inc.

Press Releases: LENZ Therapeutics, Inc.

Quotes and Performance

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-15	LENZ Therapeutics and Sarah Jessica Parker announce the launch of Make it VIZZable, the VIZZ consumer campaign	AQ
01-15	Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ	PR
01-14	LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign	GL
01-08	Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ	PR
01-08	LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates	GL

1 day	+0.41%
1 week	+4.98%
Current month	+21.97%
1 month	+10.75%
3 months	-41.85%
6 months	-41.89%
Current year	+21.97%

1 week	17.28	19.97
1 month	14.43	19.97
Current year	14.43	19.97
1 year	14.43	50.4
3 years	14.42	50.4
5 years	14.42	50.4
10 years	14.42	50.4

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LENZ THERAPEUTICS, INC.	+0.41%	+4.98%	-18.07%	-	606M
ARGENX SE	+1.08%	+0.55%	+10.89%	+91.35%	49.24B
WUXI APPTEC CO., LTD.	-0.91%	-5.78%	+75.89%	+1.08%	42.5B
INSMED INCORPORATED	-1.76%	-0.26%	+112.42%	+665.06%	34.87B
BIONTECH SE	+3.25%	-1.00%	-7.86%	-24.84%	26.49B
WUXI BIOLOGICS (CAYMAN) INC.	+3.50%	-3.47%	+105.35%	-46.18%	19.66B
GENMAB A/S	+4.38%	-8.00%	+34.87%	-23.89%	19.33B
AKESO, INC.	-3.06%	-5.47%	+90.64%	+138.49%	13.89B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.94%	-10.69%	+156.05%	-	13.23B
SUMMIT THERAPEUTICS INC.	+1.03%	-10.25%	-28.33%	+255.16%	12.38B
Average	+0.50%	-2.23%	+53.18%	+132.03%	23.22B
Weighted average by Cap.	+0.57%	-3.44%	+56.76%	+141.01%

	2025 *	2026 *
Net sales	19.07M 16.26M 15.06M 14.17M 26.37M 1.74B 28.28M 174M 68.69M 825M 71.53M 70.06M 3.01B	52.21M 44.5M 41.23M 38.78M 72.18M 4.75B 77.42M 476M 188M 2.26B 196M 192M 8.25B
Net income	-75.15M -64.05M -59.35M -55.82M -104M -6.84B -111M -685M -271M -3.25B -282M -276M -11.87B	-84.93M -72.38M -67.07M -63.08M -117M -7.73B -126M -774M -306M -3.68B -318M -312M -13.41B
Net Debt	-	-